GLPGF Galapagos NV (PK)

Mechelen,  Belgium; 21 October 2013  - Galapagos  NV (Euronext:  GLPG) announced
today a capital increase arising from employee and management warrant exercises.

Since  its inception  in 1999, Galapagos  has used  warrant plans to incentivize
personnel  and management and  have them share  in the success  of the company.
Following   warrant   exercises   during   the   exercise  period  running  from
28 September 2013 through  11 October 2013, Galapagos issued 35,719 new ordinary
shares  on  21 October 2013 for  a  total  capital  increase (including issuance
premium) of €242,874.20.

Galapagos'  Executive Committee  has put  a warrant  exercise program into place
whereby Executive Committee members have made a commitment to exercise a minimum
number  of  warrants  during  subsequent  exercise  periods,  subject to certain
conditions.   During  this  exercise  period,  three Executive Committee members
exercised warrants for a combined total of 15,000 warrants.

To  date, Galapagos' total  share capital amounts  to €161,155,270.61; the total
number  of securities conferring voting rights  is 29,791,021, which is also the
total number of voting rights (the "denominator"), and all securities conferring
voting  rights and all voting rights are of the same category.  The total number
of rights (warrants) to subscribe to not yet issued securities conferring voting
rights  is 3,675,296, which  equals the  total number  of voting rights that may
result  from  the  exercise  of  these  warrants.   Galapagos  does not have any
convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos  (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action,
with  a large pipeline of  five Phase 2 (two led  by GSK), one Phase 1, six pre-
clinical,  and  20 discovery  small-molecule  and  antibody  programs  in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other indications.
AbbVie  and Galapagos signed an agreement  in CF where they work collaboratively
to  develop and commercialize oral drugs that  address two mutations in the CFTR
gene,  the G551D and F508del mutation.  In the field of inflammation, AbbVie and
Galapagos   signed   a  worldwide  license  agreement  whereby  AbbVie  will  be
responsible  for  further  development  and  commercialization of GLPG0634 after
Phase  2B.  GLPG0634 is an orally-available, selective inhibitor of JAK1 for the
treatment  of rheumatoid arthritis and  potentially other inflammatory diseases,
currently  in  Phase  2B studies  in  RA  and  about to enter Phase 2 studies in
Crohn's  disease.  Galapagos has another selective  JAK1 inhibitor in Phase 2 in
lupus   and   psoriasis,   GSK2586184   (formerly   GLPG0778,   in-licensed   by
GlaxoSmithKline  in  2012).  GLPG0974  is  the  first  inhibitor  of  FFA2 to be
evaluated  clinically for the treatment  of IBD; this program  is currently in a
Proof-of-Concept  Phase  2 study.   GLPG1205  is  a first-in-class molecule that
targets  inflammatory disorders  and is  currently in  a First-in-Human Phase 1
study.
The  Galapagos Group, including fee-for-service  companies BioFocus, Argenta and
Fidelta,  has around  800 employees and  operates facilities  in five countries,
with   global  headquarters  in  Mechelen,  Belgium.   Further  information  at:
www.glpg.com

CONTACT

Elizabeth Goodwin, Director Investor Relations
Tel: +31 6 2291 6240
ir@glpg.com

This   release   may  contain  forward-looking  statements,  including,  without
limitation,   statements   containing   the   words  "believes,"  "anticipates,"
"expects,"  "intends,"  "plans,"  "seeks,"  "estimates," "may," "will," "could,"
"stands  to," and  "continues," as  well as  similar expressions.  Such forward-
looking  statements may involve known and unknown risks, uncertainties and other
factors  which might cause the  actual results, financial condition, performance
or  achievements of Galapagos,  or industry results,  to be materially different
from  any  historic  or  future  results,  financial  conditions, performance or
achievements  expressed or  implied by  such forward-looking  statements.  Given
these  uncertainties, the reader is  advised not to place  any undue reliance on
such forward-looking statements.  These forward-looking statements speak only as
of  the date of publication of this document.  Galapagos expressly disclaims any
obligation  to update  any such  forward-looking statements  in this document to
reflect  any change  in its  expectations with  regard thereto  or any change in
events, conditions or circumstances on which any such statement is based, unless
required by law or regulation.

Galapagos increases share capital through warrant exercises: http://hugin.info/133350/R/1736951/582215.pdf

[HUG#1736951]

Galapagos NV (PK) (USOTC:GLPGF)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

Galapagos NV (PK) (USOTC:GLPGF)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024